Cytta CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
CYCA
Cytta CORPCytta Corp. reported a significant net income for the nine months ended June 30, 2025, primarily driven by an unrealized gain on marketable securities, despite continued operational losses and a going concern warning.
OTC.Pink
CYCA
Cytta CORPCytta Corp. reported a significant shift to net income for the six months ended March 31, 2025, primarily driven by a substantial unrealized gain on marketable securities, despite continued limited operational revenue.
OTC.Pink
CYCA
Cytta CORPCytta Corp. filed an amended quarterly report, restating its Q4 2024 financials due to misstatements from fraudulent sales orders, revealing a deeper net loss and significant internal control weaknesses.
OTC.Pink
CYCA
Cytta CORP10-Q: Cytta Corp Reports Increased Revenue but Continues to Face Going Concern Challenges in Q1 2025
Cytta Corp's Q1 2025 shows revenue growth driven by subscription agreements, but the company still faces significant financial challenges and doubts about its ability to continue as a going concern.
OTC.Pink
CYCA
Cytta CORPCytta Corp. reported a decrease in revenue and an increase in operating expenses for the third quarter of 2024, alongside a net loss of $1.45 million.
OTC.Pink
CYCA
Cytta CORP10-Q: Cytta Corp. Reports Q2 2024 Results with Increased Operating Expenses and Continued Net Losses
Cytta Corp.'s Q2 2024 results show a decrease in revenue and an increase in operating expenses, leading to a net loss of $2,047,669 for the six-month period ending March 31, 2024.
OTC.Pink
CYCA
Cytta CORPCytta Corp.'s Q1 2024 results reveal a net loss of $1.059 million and continued concerns about the company's ability to operate as a going concern.